Status:
COMPLETED
Management of Superficial Thrombophlebitis
Lead Sponsor:
University of Oklahoma
Collaborating Sponsors:
Pfizer
Conditions:
Superficial Thrombophlebitis
Upper Extremity Superficial Thrombophlebitis
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
The purpose of this study is to test the hypothesis that Fragmin (dalteparin sodium) subcutaneously once daily for 7 days is more effective than Ibuprofen given orally three times daily for 7 days for...
Detailed Description
Superficial thrombophlebitis is a common problem and is thought to affect up to 20% of patients with varicose veins. In the absence of treatment, STP may cause its greatest morbidity with extension of...
Eligibility Criteria
Inclusion
- Patients with confirmed upper or lower extremity superficial thrombophlebitis by ultrasound imaging
Exclusion
- Active, clinically significant bleeding
- Known hypersensitivity to NSAIDS, heparin or derivatives
- Currently pregnant or \< 1 week post-partum
- Acquired bleeding diathesis
- Known inherited bleeding disorder
- Renal failure
- Extremes of weight
- unable to return for repeat diagnostic testing or follow-up visit
- Concurrent deep-vein thrombosis
Key Trial Info
Start Date :
October 1 2002
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2011
Estimated Enrollment :
72 Patients enrolled
Trial Details
Trial ID
NCT00264381
Start Date
October 1 2002
End Date
September 1 2011
Last Update
November 18 2013
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Veterans Affairs Medical Center
Oklahoma City, Oklahoma, United States, 73104
2
University of Oklahoma Health Science Center
Oklahoma City, Oklahoma, United States, 73104